
To characterize the temporal pattern of epiretinal membrane (ERM) development following pars plana vitrectomy (PPV) for rhegmatogenous retinal detachment (RRD) and to determine whether early postoperative optical coherence tomography (OCT) findings predict subsequent ERM formation. This retrospective longitudinal cohort study included 230 consecutive eyes undergoing primary PPV, with or without scleral buckling, for RRD. Patients underwent postoperative OCT examinations at approximately 1, 3, 6, and ≥ 12 months. Time to first OCT-confirmed ERM was determined, and demographic, ocular, and surgical characteristics were compared between eyes with and without ERM. In eyes free of ERM at the 1-month visit with complete OCT data (n = 133), multivariable logistic regression evaluated early OCT biomarkers, including intraretinal cysts (IRC), disorganization of the retinal inner layers, ellipsoid zone disruption, and subfoveal choroidal thickness, after adjustment for relevant clinical variables. ERM developed in 46 of 230 eyes (20.0
To evaluate operative time trends during early independent practice with the Yamane technique for scleral-fixated intraocular lens (SFIOL) implantation with pars plana vitrectomy (PPV), and to assess visual outcomes and postoperative complications. Retrospective, single-surgeon case series. Seventy-five consecutive eyes of 74 patients undergoing Yamane SFIOL implantation with concurrent PPV between November 2023 and October 2025. Medical records were reviewed for surgical indication, prior vitrectomy, operative time, best-corrected visual acuity (BCVA), and postoperative complications. Operative time was evaluated in 37 consecutive lens exchange cases, which were ordered chronologically and divided into early, middle, and late groups. Secondary outcomes included BCVA, complications, and follow-up. Operative time as a measure of surgical efficiency. Mean operative time decreased from 56.4 min (early) to 49.9 min (middle) and 40.7 min (late). One-way analysis of variance (ANOVA) showed a non-significant difference (p = 0.057) with a downward trend. Linear regression demonstrated a negative association between case number and operative time (y = − 0.60x + 60.12; R² = 0.15; 95
Diabetic macular edema (DME) is associated with retinal microvascular dysfunction, but the relationship between retrobulbar hemodynamics and choroidal structure remains incompletely understood. This study evaluated retrobulbar arterial hemodynamics and choroidal thickness in treatment-naïve eyes with DME and explored potential structural–hemodynamic associations. This analytical observational cross-sectional study with prospective data collection included 56 eyes of 28 treatment-naïve patients with bilateral DME and 56 eyes of 28 healthy controls. Color Doppler imaging was used to assess peak systolic velocity (PSV), end-diastolic velocity (EDV), and resistive index (RI) in the central retinal artery (CRA), short posterior ciliary arteries (SPCA), and ophthalmic artery (OA). Enhanced-depth imaging spectral-domain optical coherence tomography was used to measure subfoveal and mean choroidal thickness. Linear mixed-effects models accounting for inter-eye correlation and adjusted for age were used to evaluate between-group differences and structural–hemodynamic associations. Patients with DME were significantly older than controls (62.6 ± 7.6 vs. 40.6 ± 12.4 years, P < 0.0001). DME eyes showed significantly higher RI in the CRA, SPCA, and OA compared with controls. After adjustment for age, mean and subfoveal choroidal thickness did not differ significantly between groups. No significant group-by-hemodynamic parameter interactions were identified for mean or subfoveal choroidal thickness in the primary analyses. An exploratory post-hoc sensitivity analysis excluding one participant with extreme choroidal thinning yielded a significant interaction between SPCA PSV and mean choroidal thickness (P = 0.045). Treatment-naïve eyes with DME exhibited altered retrobulbar hemodynamics, characterized by higher resistive indices in the CRA, SPCA, and OA, whereas choroidal thickness did not differ significantly from controls after adjustment for age. Structural–hemodynamic interactions were not statistically significant in the primary analysis. These findings should be considered exploratory and warrant further investigation in larger, appropriately matched cohorts.
Central subfield thickness (CST) quantifies diabetic macular edema (DME) but does not describe accompanying retinal morphology. We examined whether baseline optical coherence tomography (OCT) microstructural burden was associated with persistent central thickening following intravitreal treatment, with baseline CST taken into account. This single-center retrospective cohort included 138 eyes of 76 patients treated with anti-vascular endothelial growth factor (anti-VEGF) agents or dexamethasone implants. An unweighted 0–4 score assigned one point for foveal eversion, more than 30 hyperreflective foci, vitreomacular interface abnormality, and ellipsoid zone disruption. Persistent central thickening was defined as CST ≥ 300 μm at month 3 (M3; 45–135 days; primary outcome) or month 6 (M6; 135–225 days; key secondary outcome). Patient-clustered logistic generalized estimating equations estimated adjusted odds ratios (ORs) per point, controlling for age, sex, baseline CST, and baseline logarithm of the minimum angle of resolution (logMAR) visual acuity; CST was analyzed continuously. Persistent thickening occurred in 88 of 118 eyes (74.6
Age-related macular degeneration (AMD) is the leading cause of irreversible central vision loss in older adults. Geographic atrophy (GA), its advanced atrophic form, now has two approved complement inhibitors as disease-modifying therapy, yet whether genetic variation predicts treatment response, and whether current genetic evidence applies beyond European populations, remains unclear. We systematically synthesized genome-wide association study (GWAS) evidence on genetic determinants of GA to address these two gaps and their implications for complement-targeted therapy. A systematic search of PubMed, Scopus, and the NHGRI-EBI GWAS Catalog was conducted from database inception through July 2026 following PRISMA guidelines. Eligible studies included human GWAS reporting GA-related genetic associations. Studies were classified as providing direct (GA-specific) or indirect evidence. Two reviewers independently performed study selection, data extraction, and methodological quality assessment using the Q-Genie instrument, and rated confidence in each finding qualitatively by directness of evidence, statistical significance, and replication (GRADE was not applicable to unpooled genome-wide evidence). Owing to heterogeneity in study design, phenotypes, and reported effect measures, findings were synthesized narratively following the Synthesis Without Meta-analysis (SWiM) guideline. Five GWAS, all conducted in predominantly European-ancestry populations, met the inclusion criteria. Two studies provided direct GA-specific evidence, and three provided indirect evidence (late AMD progression, a methodological pharmacogenomic study, and drusen traits). Complement pathway genes (CFH, C3, C2, CFB, CFI) showed the strongest associations with GA susceptibility in the single GA-specific case–control GWAS (direct evidence), with concordant but indirect (late-AMD) evidence for progression; the CFH rs1061170 (Y402H) variant had the largest reported effect (odds ratio, 2.78), while the ARMS2/HTRA1 locus was the principal non-complement susceptibility locus. In the one study that compared GA with neovascular AMD, complement variants did not discriminate between subtypes, whereas ARMS2/HTRA1 favored neovascular AMD. Longitudinal analysis of progression to late AMD (indirect evidence) identified seven loci (four established and three novel, marginally significant, model-dependent loci not supported by case-control data), and the only GA lesion-growth GWAS (direct evidence) identified PRMT6 and LSS without replication and without a complement signal. All studies were rated good methodological quality (Q-Genie), but confidence in individual findings was qualified by directness, significance, and replication: it was higher only for the complement and ARMS2/HTRA1 susceptibility loci, and no GA-specific locus was replicated in an independent GA cohort within the included studies. Only one study tested a genotype-treatment interaction, and this was a methodological study of the AREDS antioxidant/zinc formulation, not of a complement inhibitor and not GA-specific; none evaluated genotype-stratified response to pegcetacoplan or avacincaptad pegol, the two complement inhibitors currently approved for GA. No GA-specific GWAS were identified in Asian, African, or Hispanic populations. Despite two decades of consistent evidence implicating complement dysregulation in AMD, with GA-specific GWAS evidence limited to two studies, no validated pharmacogenomic biomarkers are currently established to guide genotype-based selection between approved complement inhibitors, and no GA-specific genetic evidence exists outside European populations. The absence of validated biomarkers should not be interpreted as definitive evidence that genetic variation cannot influence treatment response. These evidence gaps, rather than the established genetic architecture itself, define the current limits of precision medicine in GA. Future studies should prioritize pharmacogenomic sub-analyses of existing and future complement-inhibitor trials, alongside multi-ancestry GWAS. GA is a complex disease shaped by genetic and non-genetic factors, so genotype should not be used as the sole basis for treatment decisions. Not applicable.